EDITOR'S NOTE: The United States Department of Health and Human Services just purchased $290 million worth of Amgen’s Nplate treatment for radiation sickness due to a nuclear emergency. This is not meant to be an alarmist message, but the facts can’t be anything but alarming. There’s a strong chance that Putin isn’t bluffing with his nuclear threats. Putin may have seemed “smart” and calculated at first, but he’s indirectly telegraphed his irrational propensity for self-destruction should he end up on the losing side. And that self-destruction will likely claim the lives of many Americans, Russians, and others across the globe who may be exposed to the nuclear fallout.
- HHS is purchasing $290M worth of Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for acute radiation sickness due to a radiological or nuclear emergency.
- The treatment was developed by the company with assistance from the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases.
- Nplate is approved for immune thromocytopenia, a blood disorder characterized by low platelet counts
Originally published on Seeking Alpha.
